Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Kit for activating ovarian cancer specific immunity response

An immune response and kit technology, applied in the field of kits for enhancing anti-cancer immunity

Inactive Publication Date: 2016-01-06
SHANGHAI LONGYAO BIOTECH CO LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, DC1 cells highly expressing IL12 loaded with tumor-specific antigen peptides can provide a strategy for enhancing the efficacy of antigen peptide-based tumor therapy, but there is no corresponding, mature and suitable for the activation of ovarian cancer in the prior art. Kits for Patient-Specific Immune Responses

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Kit for activating ovarian cancer specific immunity response
  • Kit for activating ovarian cancer specific immunity response
  • Kit for activating ovarian cancer specific immunity response

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Embodiment 1 (cell culture supernatant is T cell culture supernatant)

[0033] When using the kit of the present invention to activate the specific immune response of ovarian cancer patients, the preparation of type 1 polarized dendritic cells (type1 polarized dendritic cells, DC1) derived from adult peripheral blood is firstly performed. Peripheral blood mononuclear cells were isolated according to the method described by Jonuleit et al. (GeneTher. 200310(3)). First, peripheral blood mononuclear cells were separated by Ficoll-Hypaque density gradient centrifugation, and plasma was collected for subsequent culture. By density 3.0×10 6 / ml, the cells were inoculated into T75 culture flasks, and 10% plasma was added to the GGT551 medium, placed at 37.0°C, saturated humidity, 5% CO 2 cultivated in the environment. After culturing for 3 hours, the suspended lymphocytes were washed away, and DMEM / F12 medium containing GM-CSF and IL-4 1000 IU / ml and 10% plasma was added. ...

Embodiment 2

[0038] Embodiment two (cell culture supernatant is NK cell and K562 cell co-culture supernatant)

[0039] Peripheral blood mononuclear cells were isolated according to the method described by Jonuleit et al. (GeneTher. 200310(3)). First, peripheral blood mononuclear cells were separated by Ficoll-Hypaque density gradient centrifugation, and plasma was collected for subsequent culture. IL-2 (2000U / ml) and IL15 (2ng / ml) were added. Doubling the medium every two to three days, and supplementing the factors in equal amounts. Collected on the twelfth day. After the induction is completed, NK cells are treated by 1-3×10 6 / ml was inoculated into medium RPMI1640, IFNa (1000UI / ml) was added and 0.5-1.5×10 5 Inoculate K562 cells (can be replaced with K562-NK cells) at a density of / ml for mixed culture, collect the medium supernatant during 24-48 hours of activation, filter and freeze at -80 degrees or directly use it for the preparation of DC1 cells. Peripheral blood mononuclear ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a kit for activating ovarian cancer specific immunity response. The kit comprises an RPMI-1640 culture medium, a cell culture supernatant, a GM-CSF, an IL-4, an INF gamma and an ovarian cancer specific antigenic peptide combination. The cell culture supernatant is an NK cell and K562 cell co-culture supernatant or a T cell culture supernatant. The ovarian cancer specific antigenic peptide combination includes MAGE-A1-A2 antigenic peptides, MAGE-A1-A3 antigenic peptides, MAGE-A4-A2 / 3 antigenic peptides, NY-ESO-1-A2 antigenic peptides, PLAC1-A2 antigenic peptides, CEA-A2 antigenic peptides, Mamaglobin-A-A3 antigenic peptides, hTERT-A2 antigenic peptides, hTERT-A3 antigenic peptides, Survivin-A2 antigenic peptides, Survivin-A3 antigenic peptides and MTA1-A2 antigenic peptides. The kit can efficiently activate ovarian cancer specific immunity response in an active inducing / passive inducing combined mode.

Description

technical field [0001] The invention relates to a kit for enhancing anticancer immunity, in particular to a kit for activating ovarian cancer specific immune response. Background technique [0002] Ovarian cancer is one of the common malignant tumors of female reproductive organs, and its incidence rate ranks third after cervical cancer and uterine body cancer. However, the mortality rate of epithelial ovarian cancer ranks first in all types of gynecological tumors, posing a serious threat to women's lives. Since entering the 21st century, great advances in molecular biology and immunology have provided new strategies for clinical tumor treatment. A large number of tumor cell-specific antigens have been identified by means of molecular biology, and their recognition sites by immune cells have been analyzed by means of bioinformatics, which brings the possibility of rebuilding the patient's tumor-specific immune response . However, the results of a series of clinical trial...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/0784C12N5/0783A61K39/00A61P35/00
Inventor 李伟叶圣勤汪鑫瞿苏
Owner SHANGHAI LONGYAO BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com